The matrix-degrading metalloproteinases (MMPs), particularly MMP-9, play important roles in the pathogenesis and development of malignant gliomas. In the present study, the oncogenic role of MMP-9 in malignant glioma cells was investigated via antisense RNA blockade in vitro and in vivo. TJ905 malignant glioma cells were transfected with pcDNA3.0 vector expressing antisense MMP-9 RNA (pcDNA-AS-MMP9), which significantly decreased MMP-9 expression, and cell proliferation was assessed. For in vivo studies, U251 cells, a human malignant glioma cell line, were implanted subcutaneously into 4-to 6-week-old BALB/c nude mice. The mice bearing well-established U251 gliomas were treated with intratumoral pcDNA-AS-MMP9-Lipofectamine complex (AS-MMP-9-treated group), subcutaneous injection of endostatin (endostatin-treated group), or both (combined therapy group). Mice treated with pcDNA (empty vector)-Lipofectamine served as the control group. Four or eight weeks later, the volume and weight of tumor, MMP-9 expression, microvessel density and proliferative activity were assayed. We demonstrate that pcDNA-AS-MMP9 significantly decreased MMP-9 expression and inhibited glioma cell proliferation. Volume and weight of tumor, MMP-9 expression, microvessel density and proliferative activity in the antisense-MMP-9-treated and therapeutic alliance groups were significantly lower than those in the control group. The results suggest that MMP-9 not only promotes malignant glioma cell invasiveness, but also affects tumor cell proliferation. Blocking the expression of MMP-9 with antisense RNA substantially suppresses the malignant phenotype of glioma cells, and thus can be used as an effective therapeutic strategy for malignant gliomas.
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INtRODUctION
Glioblastoma is an aggressive tumor characterized by extensive brain invasion. This infiltrative nature makes curative surgical resection almost impossible and contributes to the short median survival of glioblastoma patients.
Meanwhile, the importance of angiogenesis in glioblastoma growth was recognized many decades ago. Angiogenesis and glioblastoma invasion share common features, at least in their initial stages, as they both require controlled degradation of extracellular matrix (ECM) components in order to allow tumor cell and vascular endothelial cell migration, as well as facilitate neovascularization and tumor infiltration [1] [2] [3] [4] [5] [6] [7] [8] .
The matrix-degrading metalloproteinases (MMPs) play fundamental roles in these processes. Among the human MMPs reported to date, MMP-9 plays a vital role in the degradation of the ECM because of its substrate specificity for type IV collagen, the major component of the basement membrane. High expression levels of MMP-2 and MMP-9
have been frequently correlated with increased tumor invasiveness and poor prognosis in various types of human cancer [5, [9] [10] [11] [12] [13] . It is widely accepted that degradation of the ECM, and the consequently increased invasive capacity and metastatic potential of tumor cells, result from an imbalance between the activities of these proteases and their inhibitors [14] . These observations have created novel opportunities for developing therapeutics based on differentiation or targeting the proliferative features of malignant gliomas.
The present study was designed to investigate the effects of antisense human MMP-9 on glioma cell growth, by constructing an expression vector consisting of MMP-9
antisense cDNA against the template of MMP-9.
MAtERIALs AND MEtHODs

Plasmid constructs
The 528-bp fragment of the 5'-end of MMP- 
Western blotting Analysis
After G418 selection, individual clones were washed three times with ice-cold PBS. Then the cells were solubilized in 1% Nonidet P-40 lysis buffer (containing, in mmol/L: 20 Tris, pH 8.0, 137 NaCl, 1% Nonidet P-40, 10% glycerol, 1 CaCl 2 , 1 sodium orthovanadate, and a protease inhibitor mixture).
Homogenates were centrifuged at 20 000 g for 15 min at 4°C and protein concentrations were determined using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL).
Samples were adjusted to equal content and volume, and subjected to SDS-PAGE on 8% SDS-acrylamide gel. Proteins were then transferred to PVDF membranes (Millipore, Billerica, MA) followed by blocking. The membranes were incubated with primary antibody against MMP-9 (1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA), followed by incubation with HRP-conjugated secondary antibody (1:1 000 dilution, Zymed, Carlsbad, CA). The specific protein was detected using a SuperSignal protein detection kit (Pierce).
After washing with stripping buffer, the membrane was reprobed with antibody against β-actin (1:500 dilution, Santa
Cruz Biotechnology) using the same procedures as above.
Immunocytochemistry and Immunohistochemistry
The expression of MMP-9 and Ki-67 was assessed by immunostaining using the ABC-peroxidase method. Briefly, Immunohistochemical staining was analyzed as follows.
First, the most intensively stained area was chosen using 10× objective magnification. Four staining categories were used: "0", negative staining, only blue background seen on nuclei; "1", positive brown staining seen with difficulty and background color easily seen; "2", moderate positivity, brown staining seen better than blue background; and "3", strong positivity, background color hardly seen.
tumor Growth in vivo 
REsULts
Plasmid constructs
The fidelity and orientation of the heterogeneous fragments in the recombinant plasmids were confirmed by restriction endonuclease digestion and DNA sequencing (Fig. 1) .
Results showed that digestion of pcDNA-AS-MMP9 and 
Proliferation of transfected tJ905 Malignant Glioma cells
Immunocytochemical analysis showed that MMP-9 expression was substantially lower in TJ905 cells transfected with pcDNA-AS-MMP9 (Fig. 2C ). This finding correlated with the decrease in Ki-67 expression (a cellular marker for proliferation) (Fig. 2D) , therefore suggesting that the proliferation of malignant glioma cells was inhibited by AS-MMP9 RNA.
Antitumor Effect of MMP-9 Knockdown on U251 Glioma
Xenograft Model
Our pcDNA-AS-MMP9 and combined therapy groups (Fig. 4A) .
Tumors in the control and empty-vector groups showed much higher proliferation (Ki-67) (Fig. 4B ) and microvessel density (Fig. 4C) than those of the other therapy groups. The proliferation activity and microvessel density were lower in the combined therapy group than in either the endostatin or the pcDNA-AS-MMP9 group (Table 1) .
There were no differences between the 4-and 8-week treatments in animals receiving either AS-MMP9 alone or combined therapy, implying that antisense MMP-9 therapy continuously inhibited the proliferation of tumors for at least 8 weeks.
DIscUssION
MMP-2 and -9 belong to the matrix metalloproteinase family. Previous reports have suggested that MMP-9 is highly expressed in malignant gliomas and its expression rises with the degree of malignancy. The expression level of MMP-9 is far higher than that of MMP-2, which suggests that MMP-9 plays a role in the development and the invasive phenotype of malignant gliomas [8, 15, 16] . In the present study, we characterized the expression levels of MMP-9 using RT-PCR, Western blot and immunohistochemistry and found that both its mRNA and protein were highly expressed in TJ905 glioma cells, confirming that overexpression of MMP-9 is a stable characteristic of malignant glioma [17] . Then, we used the antisense approach to investigate In view of the fact that cultured glioma cell lines lack a tumor matrix and the positive correlation between the Ki-67 proliferation index and MMP-9 expression found in this study, we speculate that MMP-9 promotes proliferation by means of another more direct mechanism rather than remodeling cellular adhesion and the tumor matrix. Active MMP-9 is able to mobilize VEGF from its ECM reservoir.
Therefore, MMPs could promote VEGF-mediated angiogenesis in glioblastomas by both transcriptional (MT1-MMP) and post translational (MMP-9) mechanisms [2] . A recent study reported that MMP-9 releases activated insulin-like growth factor II (IGFII) after hydrolyzing the complex composed of IGFII and IGF-conjugated protein 2, which may be the mechanism resulting in the proliferation of malignant gliomas [2] . In addition, decreased pre-growth factors on the cell membrane and a weakened anti-apoptotic role of MMP-9
due to lower expression levels of the metalloproteinase also may be important causes of the inhibition of tumor cell proliferation [18] [19] [20] .
In the subcutaneous tumor model, we found that MMP-9
was overexpressed at the tumor border, where growth is fastest and the invasive potential is strongest. MMP-9
is also expressed on endothelial cells and the basement membrane of blood vessels, where proliferation and angiogenesis are active [21] [22] [23] [24] . Therefore, we speculated that MMP-9 plays multiple roles in the invasion process. On one hand, overexpression of MMP-9 may facilitate the degradation of collagen type IV and support glioma cells breaking through the basement barrier to invade the surrounding environment. On the other hand, overexpression of MMP-9 in endothelial cells would promote degradation of the vessel basement membrane [25] , encouraging endothelial cells to proliferate and migrate to form tumor microvessels [26, 27] .
We found that both a high density of microvessels and high expression of MMP-9 occurred at the edge of tumors, especially at the site of tumor invasion. We thus speculate that expression of MMP-9 may be closely connected with vascular endothelial growth [28] [29] [30] .
Expression of MMP-9 was significantly lower in the antisense MMP-9 construct and combined therapy groups than in the control and empty vector groups. However, MMP-9 expression in the endostatin group did not differ from those in control and empty vector groups. All these data suggest that antisense MMP-9 inhibited the expression of MMP-9. We used Ki-67LI to measure the proliferative activity as an estimate of the biological behavior of malignant glioma cells. We found that Ki-67LI in the AS-MMP9
construct, endostatin, and combined therapy groups was significantly lower than that in the control and empty vector groups. These data show that both AS-MMP9 and endostatin inhibit the proliferation of malignant glioma cells [31, 32] .
In addition, Ki-67LI in the combined therapy group was lower than those in the AS-MMP9 construct and endostatin groups, demonstrating that the combination has synergistic effects on proliferation. There was no difference between the 4-and 8-week groups, meaning that the treatments continuously inhibited tumor proliferation for at least 8 weeks.
The possible reasons for these observations are as follows:
(1) endostatin, an angiogenesis inhibitor, inhibits tumor progression by directly affecting tumor cells and endothelial cells [32] [33] [34] ; (2) antisense MMP-9 inhibits the transcription and translation of MMP-9 to depress the expression and impair the biological function of tumor cells, followed by a decrease in proliferation-promoting growth factors, thereby reducing tumor proliferation; and (3) low expression of MMP-9 around the microvessels inhibits remodeling of the ECM [35, 36] . Collagen type IV represents ~50% of all basement membrane proteins, and has the capacity to selfassemble into organized networks; it is crucial for basement membrane stability and assembly. Therefore, since collagen type IV is a key MMP-9 substrate, it is not surprising that suppression of MMP-9 gene expression resulted in a significant decrease in collagen type IV expression [15, 37] .
As noted above, MMP-9 plays a critical role in the malignant progression of glioma. Inhibition of MMP-9 expression with antisense MMP-9 RNA might contribute to the inhibition of malignant glioma growth and angiogenesis, as well as inhibiting tumor cell proliferation. The effect was strengthened when combined with endostatin therapy. In conclusion, this study supports the premise that MMP-9 not only promotes the invasive growth of malignant glioma cells, but also directly affects tumor cell proliferation [38] [39] [40] .
Antisense RNA technology aimed at the 528-bp sequence of MMP-9 mRNA 5' may be a valid treatment strategy for the treatment of malignant gliomas. The current study, therefore, describes a general method for the knockdown of MMP-9 gene expression that could have therapeutic applications.
